Eisai Japan’s CEO Naito: 2014 Price Revisions Are Harsh On Brands
This article was originally published in PharmAsia News
With the guidance towards generic drug use strong at Japan’s Diagnostic Procedure Combination hospitals, the situation under the new 2014 medical fee system for branded pharmaceuticals will get even harsher, Eisai CEO Haruo Naito said at a Tokyo press conference.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.